Inhibrx Biosciences Inc (INBX)
14.93
-0.52
(-3.37%)
USD |
NASDAQ |
Nov 14, 12:58
Inhibrx Biosciences Net Income (Quarterly): 1.858B for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 1.858B |
March 31, 2024 | -49.27M |
Date | Value |
---|---|
June 30, 2023 | -47.05M |
March 31, 2023 | -39.61M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-49.27M
Minimum
Mar 2024
1.858B
Maximum
Jun 2024
430.52M
Average
-43.33M
Median
Net Income (Quarterly) Benchmarks
CEL-SCI Corp | -6.857M |
AIM ImmunoTech Inc | -1.836M |
IGC Pharma Inc | -2.378M |
NovaBay Pharmaceuticals Inc | -1.585M |
Protalix BioTherapeutics Inc | -2.203M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 0.10M |
Total Expenses (Quarterly) | 161.00M |
EPS Diluted (Quarterly) | 125.48 |
Enterprise Value | -3.207M |
Earnings Yield | 776.5% |